Skip to content
10-Q

Quarterly Report

APTEVO THERAPEUTICS INC. APVO

0001193125-26-221661

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 1.25M sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.06M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 4.05K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$7.97M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.58M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.53M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $21.62M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $2.14M
Stockholders Equity Q1 2026 · Mar 31, 2026 $11.61M
Stockholders Equity Q1 2026 · Dec 31, 2025 $17.38M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$1.47M
Stockholders Equity Q1 2026 · Dec 31, 2024 $4.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.76M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.05M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.29M
Total Liabilities Q1 2026 · Dec 31, 2025 $9.81M
Current Assets Q1 2026 · Mar 31, 2026 $15.98M
Current Assets Q1 2026 · Dec 31, 2025 $23.08M
Total Assets Q1 2026 · Mar 31, 2026 $19.9M
Total Assets Q1 2026 · Dec 31, 2025 $27.19M
Eps Diluted Q1 2026 · Mar 31, 2026 −$6.41
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$1,581.81
Eps Basic Q1 2026 · Mar 31, 2026 −$6.41
Eps Basic restated Q1 2026 · Mar 31, 2025 −$1,581.81
Rd Expense Q1 2026 · Mar 31, 2026 $3.92M
Rd Expense Q1 2026 · Mar 31, 2025 $3.63M
Net Income Q1 2026 · Mar 31, 2026 −$6.7M
Net Income Q1 2026 · Mar 31, 2025 −$6.41M
Operating Income Q1 2026 · Mar 31, 2026 −$6.84M
Operating Income Q1 2026 · Mar 31, 2025 −$6.48M